

Special Issue

Innovative Prognostic Factors and Follow-Up of Localized Thoracic Malignancies

Message from the Guest Editor

During the past several decades, the use of large-range therapies and restrictive tumor-based therapeutic strategies to treat thoracic malignancies have demonstrated huge limits in terms of oncological outcome and tolerability for patients. This has highlighted the major need for changes in treatment paradigms and for adopting a more personalized and precise therapeutic approach, customized according to tumor- and patient-related factors. A challenge for multidisciplinary teams is to define the most appropriate indicators of prognosis and response to treatments, either to link to the tumor or its host. The overall aim of this Special Issue is to establish original and relevant prognostic and theranostic factors, allowing the most adequate treatment assignment and choice of treatment sequence, in a wide range of thoracic malignancies. Authors will notably focus on multidisciplinary approaches, including surgical resection, neoadjuvant and adjuvant therapies, and associated follow-up requirements. We are pleased to invite you to contribute to our Special Issue entitled “Innovative prognostic factors and follow-up of localized thoracic malignancies”.

Guest Editor

Dr. Ludovic Fournel

Thoracic Surgery Department, Assistance Publique—Hopitaux de Paris,
Hôpital Cochin, 75014 Paris, France

Deadline for manuscript submissions

closed (30 June 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/130443

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)